Impact of metformin on reproductive tissues: an overview from gametogenesis to gestation

Michael J. Bertoldo*, Melanie Faure*, Joelle Dupont, Pascal Froment

Unité de Physiologie de la Reproduction et des Comportements, Institut National de la Recherche Agronomique, Centre Val de Loire, UMR85, 37380 Nouzilly, France

*These authors contributed equally to this work.

Correspondence to: Dr. Pascal Froment. Unité de Physiologie de la Reproduction et des Comportements, Institut National de la Recherche Agronomique, 37380 Nouzilly, France. Email: pascal.froment@tours.inra.fr.

Abstract: Metformin is an oral anti-hyperglycemic drug that acts as an insulin sensitizer in the treatment of diabetes mellitus type 2. It has also been widely used in the treatment of polycystic ovary syndrome (PCOS) and gestational diabetes. This drug has been shown to activate a protein kinase called S' AMP-activated protein kinase or AMPK. AMPK is present in many tissues making metformin's effect multi factorial. However as metformin crosses the placenta, its use during pregnancy raises concerns regarding potential adverse effects on the mother and fetus. The majority of reports suggest no significant adverse effects or teratogenicity. However, disconcerting reports of male mouse offspring that were exposed to metformin in utero that present with a reduction in testis size, seminiferous tubule size and in Sertoli cell number suggest that we do not understand the full suite of effects of metformin. In addition, recent molecular evidence is suggesting an epigenetic effect of metformin which could explain some of the long-term effects reported. Nevertheless, the data are still insufficient to completely confirm or disprove negative effects of metformin. The aims of this review are to provide a summary of the safety of metformin in various aspects of sexual reproduction, the use of metformin by gestating mothers, and its possible side-effects on offspring from women who are administered metformin during pregnancy.

Keywords: Metformin; fertility; ovary; testis; pituitary

Submitted Apr 14, 2014. Accepted for publication May 21, 2014.
doi: 10.3978/j.issn.2305-5839.2014.06.04

View this article at: http://dx.doi.org/10.3978/j.issn.2305-5839.2014.06.04

Introduction

Metformin is the most widely used drug for reproductive abnormalities associated with insulin resistance and also the oldest insulin sensitizer in the therapeutic management of type 2 diabetes mellitus. Its action reduces hepatic glucose output, increases tissue insulin sensitivity and enhances peripheral glucose uptake, resulting in lower concentrations of glucose without the associated risk of either hypoglycemia or weight gain (1,2). Metformin is a stable hydrophilic biguanide compound that is highly polar, positively charged with a low molecular weight and has pleiotropic actions. It is present in a number of tissues including muscle, liver, pancreas, adipose tissue, hypothalamus, pituitary and the gonads. Despite low lipid solubility, some subcellular studies in rat liver showed that metformin is mainly localized in the cytosol (3) and studies in mice show that metformin may accumulate in certain tissues at higher concentrations than in plasma (4). The passive diffusion of metformin into cells is limited (5), the main transport is the organic cation transporter 1-3 or multdrug and toxic compound extrusion type transporters (MATE1, MATE2) which are able to internalize metformin as described in gut, hepatocytes, renal tubular epithelial cells and reproductive tissues (6). One of the direct effects of metformin identified is to inhibit the activity of the respiratory electron transport chain in mitochondria (7) and to activate the cytoplasmic protein kinase known as AMP-activated protein kinase (AMPK) (8). AMPK is an important sensor of cellular energy homeostasis and is sensitive to the AMP:ATP ratio (9,10). We can note that several
studies have also demonstrated that metformin might act independently of AMPK (11-13). A deficiency in ATP activates AMPK leading to increased energy production including glucose and lipid catabolism and an inhibition of energy consuming processes such as protein, fatty acid and cholesterol synthesis.

These metabolic pathways are highly utilised by reproductive tissues which produce steroids, peptides hormones, and where proliferative cells are present. Furthermore, metformin administration has been used in women who present with perturbed fertility associated with insulin resistance. Indeed, women with polycystic ovary syndrome (PCOS) were treated with clomiphene citrate associated or not with metformin to improve ovulation rate (14-16).

The aims of this review are to provide a critical summary of the safety of metformin on various aspects of sexual reproduction, especially the possible side-effects on gonads of offspring from women who are administered metformin during pregnancy.

**Metformin and central control of reproduction**

Fertility is controlled centrally at least in part by gonadotropin-releasing hormone (GnRH) neurones that are located in the hypothalamus. These neurones secrete GnRH which stimulate lutetinizing hormone (LH) and follicle stimulating hormone (FSH) secretions by the pituitary. GnRH neurones are responsive to numerous stimuli including peripheral metabolic signals such as glucose and leptin (17,18). AMPK has been widely studied in the brain as it is involved in regulating food intake, a function regulated by the hypothalamus (19-22). The various anorectic signals (leptin, insulin, glucose) reduce AMPK activity whereas the orexigenic signals (ghrelin, neuropeptide Y) increase AMPK activity which permits regulation of food intake (23,24). In the brain, metformin inhibits AMPK activity in the hypothalamus and neuropeptide Y neurones which explains the appetite suppressing nature of AMPK (25). In the same region of the brain, the functioning of neurones to kispeptin and to GnRH seems also to be AMPK dependent. Intracerebroventricular (ICV) injection of another AMPK activator, AICAR, inhibits 60% of the kispeptin-positive neurones from the arcuate nucleus of the hypothalamus, and conversely injection of an AMPK inhibitor, compound C, increases 2-fold the number of kispeptin positive neurones (26). The ICV injection of AICAR in rat stimulated hypothalamic AMPK activation and increased the duration of the period of oestrus and reduced the inter-estrus interval (19). In ewes, injection of two activators of AMPK (metformin and AICAR) reduced the amplitude of the circadian rhythm of melatonin which is a key regulator in the control seasonality of reproduction (27). As a consequence, AMPK is a key participant in the operation of important reproductive neuron regulators (Figure 1).

AMPK has previously been shown to be present in the rat pituitary (28). While there appears to be no effect on FSH secretion (29), in women administered metformin for treatment with PCOS a reduction in LH secretion is observed (29-31). This reduction appears to be due to a reduction in pulse amplitude and not pulse frequency (31) and it is accepted that menstrual cycles can be corrected with metformin treatment (32,33), which indicates restoration of the hypothalamic—pituitary axis. This is in contrast to the rat where Tosca et al. (28) observed a reduction in both FSH and LH, and Lu et al. (34) observed a reduction in LH secretion. When activated by metformin, AMPK inhibited GnRH-stimulated FSH and LH release by a MAPK3/1 mediated pathway and activin-stimulated FSH release by a SMAD2 dependent pathway (28). These reductions in gonadotropin secretion would likely then result in diminished steroid synthesis in the ovary.

**Metformin and the adult testis**

Male fertility is influenced by nutrition and energy metabolism. Indeed, we find among marathons who have little energy reserve (35) or conversely in cases of obesity, reduced sperm production (36). As early as the 1970’s, the relationship between lipid metabolism and male fertility was addressed through the use of linoleic acid (37). More recently with the use of animal models, it has been possible to show that the synthesis of polyunsaturated fatty acids (PUFA) with long-chains are present in cell membranes (including sperm), and are provided by the transformation of essential PUFA n-3 and n-6 by the Sertoli cells in rats (38).

There is evidence that metformin inhibits complex I of the mitochondria respiratory chain thereby reducing mitochondrial function and cellular respiration, leading to anaerobic respiration and an increase in lactate secretion (7). Lactate is the primary energy substrate for male germ cells and is produced by the Sertoli cells. Thus, stimulation of rat Sertoli cells with metformin or AICAR-mediated AMPK activation resulted in a 3-fold increase in lactate production (39). Together these results suggest a role for AMPK and metformin modulating the nutritional function of Sertoli cells (Figure 2).
accordance with this production, we found that mRNA level of glucose transporter Glut1 and lactate dehydrogenase LDH, which catalyzed the conversion of pyruvate to lactate, tended to increase. Similarly, upregulation of Glut1 and LDH expression has also been described in rat Sertoli cells after AICAR treatment (39).

Metformin administered to rabbits with alloxan-induced (type 1) diabetes has been demonstrated to reduce testicular weight, sperm cell count, sperm motility, and an increase in the number of dead and abnormal sperm (51), suggesting adverse effects on male fertility. Furthermore, the long-term use of some anti-diabetic drugs has been reported to produce mutagenicity and nuclear damage (52,53). In addition, the treatment of sperm with a known natural activator of AMPK, resveratrol reduced DNA damage and lipid peroxidation (54-56). As metformin is administered to males for diabetes, it was pertinent to assess the effects of metformin on sperm function and fertilizing capacity when it was added in sperm cryopreservation media of mouse sperm (50). Under the conditions of our study, the results demonstrated that the presence of metformin in the cryopreservation media induced an improvement in the fertilization rate and a reduction in the proportion of abnormal embryos after in vitro fertilization (50). This increase in AMPK activity was associated with an increase in IVF success that could be linked to results described in a species of arctic frog (Rana sylvatica) with high cryotolerance (57). Interestingly, during the freezing of frog tissues, AMPK activity increases 2.5- to 4.4- fold (57,58), suggesting that AMPK is involved in the natural responses to freezing and thawing. In contrast, the results obtained with fresh sperm in Bertoldo et al. are in accordance to those of Hurtado de Llera et al. (59) who observed a partial reduction in motility of boar sperm following 5,000 µM treatment with metformin in fresh sperm for two hours.

**Maternal insulin resistance and management of Reproduction and Pregnancy**

**Metformin and the adult ovary—PCOS**

PCOS affects 5% to 10% of women in reproductive age and represents the most common cause of infertility (75% of cases of anovulatory infertility) that is associated with anovulation, hyperandrogenism and metabolic disturbance (60). Considerable research effort has been
directed towards the administration of metformin for the treatment of PCOS (61). Furthermore, the therapeutic strategy facing a patient presenting with PCOS is in general, well defined.

Clomiphene citrate, an estrogen receptor inhibitor, is used to restore ovulation and thus promote follicle development in these patients by reducing the negative feedback effects of estrogen on the hypothalamus. Then metformin usually prescribed in the treatment of type 2 diabetes, may be administered for its insulin-sensitizing properties, and to facilitate the decrease circulating levels of androgens (43). In this context, metformin is given to improve the effectiveness of clomiphene citrate (62). To clarify the mechanism of metformin’s action on the cell types implicated in ovarian function, several research groups have studied the activity of AMPK in the different ovarian cell types. AMPK is present in all cell compartments of the ovary in all the domestic species studied to date (cow, goat, sheep and pig), the rat, humans and also in chickens. Expression could be changed in function the maturation stage. In hens, AMPK phosphorylation

Figure 2 Role of metformin in steroidogenesis and gametogenesis in ovary and in testis (40-50).
decreases in granulosa cells during terminal folliculogenesis, suggesting a role of this kinase during the pre-ovulatory period (Figure 2) (40).

Different studies have been conducted to determine if the action of metformin on the ovary is direct or indirect (28,40,41,63). Even if the mechanism of metformin action is still unclear, several studies have suggested actions of metformin in granulosa cell steroidogenesis and oocyte maturation (45). In adolescent girls with precocious onset of puberty, metformin administration has permitted a reduction in excess androgens (64), several studies have shown that metformin can lead to a diminution of systemic androgen in women experiencing PCOS (65,66). However, others authors have observed that results are not due to metformin alone (67).

Similar observations mainly in vivo or in ovarian cell culture models have been described in several species (human, rodents, cow and goat) where reductions of estradiol, progesterone from the granulosa and even androgen by human thecal cells was observed (42,43) in vivo and in vitro (68). The reduction in progesterone synthesis in the presence of metformin only occurs following the stimulation of cells with either FSH, IGF-1 alone, or together (41,42). Metformin exerts an effect on the gene expression of proteins involved in steroid production (CYP11A1, 3βHSD, aromatase) as we have reported by qRT-PCR analysis, but also at the protein activity level in bovine granulosa cells (41,42). In addition, in rat primary granulosa cells, metformin reduced estradiol and progesterone after only 3 h of stimulation (41). Metformin is also capable of stimulating in vitro lactate production by human granulosa cells (69).

Following the incubation of a human theca cell line with metformin, a reduction in the synthesis of androstenedione was observed (43). In cultures of primary cells of theca interna from the rat, the addition of metformin was correlated with increased activity of AMPK and inhibition of proliferation induced by insulin stimulation (44). However, in the latter study, the authors did not assess steroidogenesis. Metformin may therefore lead to decreased androgen synthesis through activation of AMPK and a reduction in proliferation of theca cells. Consequently, less aromatizable androgen would be available to granulosa cells to produce estradiol. Indeed in the rat, the activation of AMPK in granulosa cells inhibits their proliferation (46,70). As observed in granulosa cells, AMPK is involved in the luteal synthesis of progesterone. In the bovine corpus luteum, LH activity inhibits AMPK activation as the AMPK activator AICAR decreases the synthesis of LH-stimulated progesterone in the cow (71).

In addition, adipokines which are cytokines produced mainly by adipose tissue and also by the gonads could modify steroid production. Thus, it was recently demonstrated that visfatin is present in all cellular compartments of the ovary and that metformin increases visfatin expression via AMPK and SIRT1 in human granulosa cells (72). In addition, visfatin increased IGF1-but not FSH-induced steroid secretion (72), highlighting another level of regulation on ovarian steroidogenesis by metformin and AMPK.

Another action of metformin is its involvement in oocyte maturation. Indeed, in bovine and porcine oocytes, metformin blocked meiotic progression to the germinal vesicle stage (45,73). In bovine oocytes, meiotic arrest was associated with increased AMPK activity, reduced MAPK3/1 phosphorylation in both oocytes and cumulus cells, and the latency of two key factors (RPS6 and EEF2) involved in protein synthesis in oocytes. In addition, these effects were only evident in cumulus-oocyte complexes and not in denuded oocytes, indicating that at least in the bovine, cumulus cells are essential for metformin to exert an effect on the oocyte (45). Furthermore in the marine worm, Cerebratulus lacteus, as in the bovine and porcine models, oocyte maturation is correlated with the inhibition of the AMPK complex (74). As mouse oocytes do not require rounds of protein synthesis, species effect differences may be attributed to an inhibitory effect on key proteins for meiotic progression. More studies will be needed to determine the role of AMPK as it appears there are significant differences between species.

Metformin and gestational diabetes

In contrast to metformin administration for PCOS (Figure 3), metformin in women with gestational diabetes is absent around the time of terminal oocyte maturation, conception and early embryo development with in utero exposure occurring in the second and third trimesters. The placenta plays a central role in the transfer of drugs between the mother and the unborn young and metformin could directly affect fetal physiology and embryonic development as it crosses the placenta (89,90). Despite this, metformin is currently listed as a category B drug for use during pregnancy, meaning that animal reproduction studies (91) have failed to demonstrate a risk to the fetus, yet there are no adequate and well-controlled studies in pregnant women (92). Thus,
Metformin has been detected in umbilical cord blood at levels equal to that in maternal venous blood (93). Hughes et al. observed that clearance of metformin in women with type 2 diabetes increases during pregnancy as a result of enhanced renal clearance (94). Consequently, although there appears to be a paucity of information available, the results suggest that to maintain a therapeutic effect, a greater than 20% increase in the dose is perhaps required (92,94), resulting in greater concentrations of systemic metformin and increased fetal exposure (95).

Recent data have observed that use of insulin sensitizers and metformin, during the first 12 weeks of gestation or more, reduced development of gestational diabetes and did not influence the health of babies, and no obstetric complications or congenital anomalies were described (Figure 3) (80). Appropriate metformin therapy during gestational diabetes can decrease both maternal and fetal morbidity, particularly congenital abnormalities, neonatal hypoglycemia and macrosomia, and fetal loss (85,96,97). Data suggest that metformin used during the first gestational trimester is not teratogenic (75,82,98,99).

However, metformin has been reported to increase the rate of preterm birth (100). Infants of diabetic mothers exposed to metformin in utero can experience a reduction in insulin resistance, which may have an advantageous effect on adipose tissue distribution. When mothers with gestational diabetes were administered either metformin or insulin, metformin exposed children had larger measures of subcutaneous fat, but overall body fat was the same two years after the birth of the children (101). However, no differences were observed between the two groups in terms of central fat measures, total fat mass or percentage of body fat. Compared to those children exposed to insulin in utero, those exposed to metformin had larger upper arm circumference and bigger biceps and subscapular skin folds, indicating a more favorable pattern of fat distribution, and consequently less predisposed to insulin resistance and the adverse metabolic consequences of obesity than children exposed to insulin (92,101). These results have been supported by smaller but comparable studies (84-87,100,102). Overall metformin did not increase the risk of neonatal complications and may have been responsible for

<table>
<thead>
<tr>
<th>Metformin effects on the mother</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCOS</td>
</tr>
<tr>
<td>Miscarriage risk ↓ (75-79)</td>
</tr>
<tr>
<td>Identical period of pregnancy (80,81)</td>
</tr>
<tr>
<td>Identical pre-eclampsia risk (79,80)</td>
</tr>
<tr>
<td>Identical cesarean birth (81)</td>
</tr>
<tr>
<td>Identical BMI (76-79,81)</td>
</tr>
<tr>
<td>Identical body weight gain (78,82)</td>
</tr>
<tr>
<td>SHBG ↑, identical level of DHEA, DHEAS, androstenedione, testosterone, DHT, ADG, estrone, estradiol, estritol (83): PCOS and for LH, FSH, estradiol, testosterone and androstenedione too (16): PCOS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gestational diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miscarriage risk ↓ (84)</td>
</tr>
<tr>
<td>Identical pre-eclampsia risk (84-86)</td>
</tr>
<tr>
<td>Identical cesarean birth (84-86) or ↑ (87)</td>
</tr>
<tr>
<td>Identical BMI (84,85)</td>
</tr>
<tr>
<td>Body weight gain ↓ (compared to control with insulin treatment) (84)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Metformin effects on the foetus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational diabetes</td>
</tr>
<tr>
<td>Identical congenital anomaly (76,80-82)</td>
</tr>
<tr>
<td>Identical premature birth (80,82): PCOS / (85): GDM or ↓ (78): PCOS</td>
</tr>
<tr>
<td>Identical gestational death (82)</td>
</tr>
<tr>
<td>Live birth rates ↑ in PCOS (75,78,79): PCOS</td>
</tr>
<tr>
<td>Identical birthweight and height (75,79,82,88) or ↓ for female (80): PCOS or ↓ (84,85): GDM (control treated with insulin)</td>
</tr>
</tbody>
</table>

**Figure 3** Role of metformin during gestation and consequences on the fetus (16,75-88).
a decrease in neonatal hypoglycemia compared with insulin treatment.

With most findings consistent between studies, the use of metformin during gestational diabetes appears favorable. While there were inconsistencies in the rate of preterm births (100), all the above studies confirm that metformin is safe, with no significant maternal or neonatal adverse effects, and that metformin has improved neonatal outcomes compared with insulin. However, critically these studies lack the proper controls in terms of administration of neither metformin nor insulin which are needed to assess the long-term health of offspring. In spite of the overall available evidence, the literature is still inadequate to establish the long-term safety on offspring.

**Metformin and fetal development**

Metformin was in some studies administrated at the beginning of pregnancy, because, metformin treatment during pregnancy reduced the occurrence of miscarriage (75-79). However over an extended period, studies have observed that metformin has the ability to cross the placenta (89,90), and its use during pregnancy raises concerns about potential adverse effects on both the mother and fetus (91,92,103). Some studies have observed that in utero exposure to metformin early in pregnancy does not appear to cause any adverse effects or congenital malformations (75,78,79,81,82,99). Despite this, consequences on gonad development of the fetus have not been clearly studied.

Indeed, the first morphological sign of testicular differentiation is the maturation of Sertoli cells leading to the formation of testicular cords, 11.5 days post-coitum (dpc) in mouse and between 6-7 weeks post-fertilization in human. Subsequently, fetal Leydig cells secrete testosterone from 12 dpc in mice (104-106). Within the seminiferous cords, germ cells called gonocytes proliferate and give rise to spermatogonial stem cells during postnatal life. The integrity of gonocytes is crucial for fertility in adulthood and for avoiding transmission of genetic modifications. Thus, when altered fetal androgen production interferes with masculinization it can result in disorders of sexual differentiation, phenotypic sex reversal, or more commonly, cryptorchidism and hypospadias. These disorders are recognized to be risk factors for low sperm counts and development of testicular cancer in adulthood (107).

At birth, babies from mothers treated by metformin to reduce the risk of gestational diabetes or treatment of fertility in case of PCOS do not present malformation or locomotor abnormalities (75,78,79,81,82,99). Even at three, six and eighteen months of life, metformin did not cause any adverse effects in terms of weight and motor skills (Figure 3) (80). Conversely at twelve months of age, Carlsen et al. (88) observed in utero metformin-exposed children were heavier when compared to placebo treated children. In a longitudinal study of the offspring of mothers treated with metformin for PCOS, there were no differences in height, weight or body composition at eight years of age between those exposed to metformin or the placebo (108).

In addition, after controlling for pregnancy complications, neonatal hypoglycemia (82) and the mean birthweight percentile of neonates exposed to metformin (81) was significantly lower than that of neonates delivered to normal healthy matched controls. Evidently, further research is required to confirm or disprove these and other potential effects of in utero exposure of metformin later in life (108).

During fetal testis development, two main functions take place: gametogenesis and steroidogenesis. The commencement of testosterone production is important as it is involved in masculinization. The first trimester of pregnancy is a window where gonads are sensitive to exogenous substances due to the first step of gonad differentiation. Preliminary human evidence has shown, that compared to non-exposed controls, metformin exposed offspring have not been reported to differ in male and female steroids (83) or anti-müllerian hormone (AMH), a hormone involved in the differentiation of the male tract (109). In spite of these reports, the free testosterone index (FTI), which is the ratio used to evaluate the androgen status in humans and is calculated by the total testosterone level divided by the sex hormone binding globulin (SHBG) level, was increased in metformin-exposed male offspring (109). In addition, an increase in levels in SHBG newborns exposed to metformin during the first trimester of pregnancy has also been reported (83). It would be anticipated that in an increase in SHBG would result in a lower free androgen indexes (FAI). SHBG is a glycoprotein that binds androgens and estradiol and modulates their biological properties. This premise supports the results of the Carlsen and Vanky study (83) but does not explain those of Vanky and Carlsen (109) which remain unsettled.

However, in vitro studies and in vivo experiments in mouse models have reported on the consequences on androgens production. Organotypic culture systems using human and mouse testis demonstrated similar effects of metformin where a reduction in testosterone synthesis but an increase in lactate production was observed (48). Lactate is an energy
substrate for germ cells. Nonetheless, the human testis is more sensitive to metformin than mouse testis. Hence, a concentration of only 50 µM metformin in human testis culture leads to a 45% decrease in testosterone secretion whereas 500 µM of metformin is needed in mouse culture to obtain a 20% decrease in testosterone release (48). So even if testosterone synthesis is reduced and another marker called, \( \text{Insl3, mRNA} \) is greatly inhibited by metformin in mouse testicular explants \textit{in vitro}, no alteration of testis descent was observed in these mice treated \textit{in utero} (48). Given the results, it could be interesting to measure the anogenital distance in new born males which is considered a marker of fetal androgen action (48).

An important consequence associated with these modifications of the endocrine system was that \textit{in utero} metformin-exposed new borns presented with a decrease in testis size, tubule diameter and a lower Sertoli cells number than control mice (48). Certainly, the Sertoli cell population determines the efficiency of spermatogenesis (110), and there is a strong correlation between the number of Sertoli cells, the number of germ cells interacting with them, sperm production and finally the testicular volume. These results raise some questions about harmlessness of metformin on gonad development and the fertility of the progeny from treated mothers, where we have no data at this time.

**Metformin & epigenetics**

In mice, oocyte maturation \textit{in vitro} could be stimulated by activation of AMPK. AMPK is involved in oocyte for condensation of chromatin and formation of the meiotic spindle at the resumption of meiosis (47,111). Thus, AMPK has been shown to directly associate with chromatin to regulate transcriptional programs required to respond and survive to a wide variety of environmental stresses (112). It exerts its effect on the chromatin by phosphorylating histone H2B at serine 36 or by regulating histone deacetylases (HDAC), a class of enzymes that remove acetyl groups on histones. When this process is perturbed, lower cell survival and response to stress is observed (112). We have shown that genetic ablation of AMPKα1 in Sertoli cells results in reduced phosphorylated histone H2B associated with a reduction in Sertoli cell function and reduced sperm function and fertility. Together these results highlight the importance of AMPK in responding to stress and proper cell function and the potential long-term effects if AMPK signaling is perturbed.

While the immediate effects of metformin in the treatment of PCOS and diabetes have been relatively well characterised, data on the longer term effects of metformin is lacking. Salomäki \textit{et al.} (91) hypothesized that prenatal metformin exposure possibly has longer term effects on the offspring. In mice it was demonstrated that fetal metformin exposure programs the metabolic phenotype of the offspring. This included an increase in fetal weight at day 18 post-coitum without affecting maternal weight development or food intake. When the progeny were fed a high fat diet, prenatal metformin exposure led to increased body weight gain, a reduction in total body water content and an increase in mesenteric fat and liver weight at the end of the high fat diet phase (91). In addition, male offspring exposed to metformin exhibited impaired glucose tolerance and elevated fasting glucose during the high fat diet.

Caton \textit{et al.} (113) proposed that metformin increased hepatic SIRT1 activity, an histone deacetylase, through AMPK-mediated induction of nicotinamide phosphoribosyltransferase (NAMPT). Recently we assessed the effects of metformin supplementation in the cryopreservation media of mouse sperm (50). The activity of SIRT1, which can be modulated by metformin through AMPK, was increased in the presence of pharmacological doses of metformin. HDACs are present in elongated spermatids and spermatozoa at various stages of development (114-116). It has previously been reported that HDAC deacetylates some proteins associated with mitochondrial function or metabolism such as CRTC2 or PGC1α, but also histones. It will be necessary to determine the exact role of metformin in the proper programming of the epigenome as our results suggest that metformin has the capability of altering histone acetylation (50).

**Conclusions**

The literature examined in the present review, support the premise that metformin is safe to use during pregnancy with respect to immediate pregnancy outcomes. However, while the preliminary results of longitudinal studies in progress are encouraging, we still do not have adequate data to say with any certainty that metformin does not have any adverse effects for whole of life health. Indeed, when reviewing the literature it becomes apparent that numerous methodological issues are relevant since they affect the interpretation of some of the studies published on pregnancy outcomes (92,117,118). Presently most studies have been conducted retrospectively and conducted at various centers across many countries, in addition many studies include a small sample size, thus limiting.
the validity of results. Nonetheless, advancements in our understanding in the molecular modes of action of metformin are progressing. Whether pregnant women should be administered metformin remains controversial (92).

While there is no evidence of teratogenicity associated with metformin treatment when used during pregnancy, data presented in the present review raise questions of safety in terms of fetal testicular development. Ambiguity in the results of studies will ensure that this controversy remains.

Acknowledgements

Melanie Faure was supported by the Region Centre and Institut National de la Recherche Agronomique. This work was financially supported by Institut National de la Recherche Agronomique (INRA) and the national program FERTiNERGY funded by the French National Research Agency (ANR).

Disclosure: The authors declare no conflict of interest.

References

22. Kim EK, Miller I, Aja S, et al. C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-
46. Kayampilly PP, Menon KMJ. AMPK activation by
70. Kayampilly PP, Menon KM. Follicle-stimulating hormone inhibits adenosine 5’-monophosphate-activated protein kinase activation and promotes cell proliferation of primary granulosa cells in culture through an Akt-dependent pathway. Endocrinology 2009;150:929-35.


107. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001;16:972-8.


